 |
 |
Amerin stock surges by 20pc on drug results Charlie Weston AMERIN, the drug company chaired by former Elan finance director Tom Lynch, saw its shares rise 20pc in early trading on the Nasdaq last night. Amerin can count among its shareholders some wealthy Irish investors. The shares hit $1.84 (€1.53), which means the stock has now risen by 50pc in 2006. Amerin recently revealed promising results from two studies investigating its Miraxion drug as a treatment for Parkinson's disease. It also recently signed a deal licensing worldwide rights to a multiple sclerosis drug. This deal could see Amerin reap up to €275m in milestone payments. Just before Christmas the company raised $26.4m to fund what it hopes will be the final phase of trials for Miraxion as a treatment for Huntington's disease. The company, which was spun out of Elan, is considering a move to the Alternative Investment Market in London and Dublin's IEX - a move that would please investors on this side of the Atlantic. It is based in London, with a large Irish following, but listed in America. ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn